Summary:
- Eli Lilly, a leading pharmaceutical company, has announced plans to acquire Centessa Pharmaceuticals, a clinical-stage biopharmaceutical company.
- The acquisition aims to advance the development of treatments for sleep disorders, a growing area of medical research and unmet need.
- Centessa's pipeline includes several promising drug candidates that target different aspects of sleep regulation, which could lead to new and improved therapies for patients suffering from various sleep-related conditions.